Beyond the theoretical inhibition of Aβ peptide clearance, other potentially AD-risk pathways exist, such as increased bradykinin and natriuretic peptides [7], and also potentially protective pathways, such as increased neuroprotective peptides (neuropeptide Y, substance P, glucagon-like peptide 1 GLP-1) [7]. This evidence concerns the gene GCG and Alzheimer disease.